SBFM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SBFM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sunshine Biopharma's total current assets for the quarter that ended in Mar. 2024 was $28.83 Mil.
The historical data trend for Sunshine Biopharma's Total Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Current Assets | Get a 7-Day Free Trial | 0.07 | 1.03 | 2.20 | 27.31 | 24.89 |
Sunshine Biopharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Current Assets | Get a 7-Day Free Trial | 24.95 | 26.10 | 25.44 | 24.89 | 28.83 |
Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.
Sunshine Biopharma's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 16.292 | + | 2.552 | + | 5.735 | + | 0.311 | |
= | 24.89 |
Sunshine Biopharma's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as
Total Current Assets | = | Cash, Cash Equivalents, Marketable Securities | + | Total Receivables | + | Total Inventories | + | Other Current Assets |
= | 17.434 | + | 2.828 | + | 7.698 | + | 0.871 | |
= | 28.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Sunshine Biopharma (NAS:SBFM) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Sunshine Biopharma's Liquidation Value for the quarter that ended in Mar. 2024 is
Liquidation value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 17.434 | - | 7.079 | + | 0.75 * 2.828 | + | 0.5 * 7.698 |
= | 16.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sunshine Biopharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Camille Sebaaly | director, officer: CFO and Secretary | 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1 |
Malek Chamoun | 10 percent owner | 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Andrew Mark Keller | director | 10 ISLAND DRIVE, NORWALK CT 06855 |
Andrew I Telsey | director | 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111 |
James Daniel Kish | director | 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111 |
Rabi Kiderchah | director | 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3 |
Advanomics Corp | 10 percent owner | 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
Steve N. Slilaty | director, 10 percent owner, officer: CEO and President | 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
Abderrazzak Merzouki | director, officer: Chief Operating Officer | 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1 |
Turi Michele Di | director, officer: Chief Operating Officer | 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 04-08-2022
By Stock market mentor Stock market mentor • 01-19-2023
By ACCESSWIRE ACCESSWIRE • 02-10-2021
By GuruFocusNews GuruFocusNews • 03-10-2022
By ACCESSWIRE ACCESSWIRE • 05-16-2023
By GuruFocusNews GuruFocusNews • 04-28-2022
By PurpleRose PurpleRose • 08-04-2022
By sperokesalga sperokesalga • 05-16-2023
By sperokesalga sperokesalga • 05-12-2023
By Marketwired • 08-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.